GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Shiller PE Ratio

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Shiller PE Ratio

: 11.75 (As of Today)
View and export this data going back to 1995. Start your Free Trial

As of today (2024-04-19), Ligand Pharmaceuticals's current share price is $72.47. Ligand Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $6.17. Ligand Pharmaceuticals's Shiller PE Ratio for today is 11.75.

The historical rank and industry rank for Ligand Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

LGND' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.13   Med: 18.13   Max: 266.47
Current: 11.75

During the past years, Ligand Pharmaceuticals's highest Shiller PE Ratio was 266.47. The lowest was 8.13. And the median was 18.13.

LGND's Shiller PE Ratio is ranked better than
87.5% of 144 companies
in the Biotechnology industry
Industry Median: 32.26 vs LGND: 11.75

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.030. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $6.17 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Ligand Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.40 12.50 17.21 11.60 11.57

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.60 12.10 11.78 9.82 11.57

Competitive Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Shiller PE Ratio falls into.



Ligand Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ligand Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=72.47/6.17
=11.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Ligand Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.03/129.4194*129.4194
=1.030

Current CPI (Dec. 2023) = 129.4194.

Ligand Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.100 99.695 0.130
201406 0.070 100.560 0.090
201409 0.060 100.428 0.077
201412 0.340 99.070 0.444
201503 0.040 99.621 0.052
201506 1.110 100.684 1.427
201509 9.280 100.392 11.963
201512 0.290 99.792 0.376
201603 0.300 100.470 0.386
201606 -0.300 101.688 -0.382
201609 0.050 101.861 0.064
201612 -0.150 101.863 -0.191
201703 0.220 102.862 0.277
201706 0.260 103.349 0.326
201709 0.360 104.136 0.447
201712 -0.330 104.011 -0.411
201803 1.830 105.290 2.249
201806 2.990 106.317 3.640
201809 2.800 106.507 3.402
201812 -2.020 105.998 -2.466
201903 31.320 107.251 37.794
201906 -0.740 108.070 -0.886
201909 -0.810 108.329 -0.968
201912 -0.430 108.420 -0.513
202003 -1.460 108.902 -1.735
202006 1.320 108.767 1.571
202009 -0.420 109.815 -0.495
202012 0.350 109.897 0.412
202103 1.050 111.754 1.216
202106 1.790 114.631 2.021
202109 0.800 115.734 0.895
202112 -0.300 117.630 -0.330
202203 -0.910 121.301 -0.971
202206 -0.050 125.017 -0.052
202209 0.020 125.227 0.021
202212 -1.040 125.222 -1.075
202303 2.330 127.348 2.368
202306 0.130 128.729 0.131
202309 -0.590 129.860 -0.588
202312 1.030 129.419 1.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ligand Pharmaceuticals  (NAS:LGND) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ligand Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Headlines

From GuruFocus